⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL633799 | 1.00 | — | — | |
| SCHEMBL1095061 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL2113214 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL6067784 | 0.98 | L3MBTL1 (0.41) | — | |
| Hydrochloric Acid SCHEMBL3224238 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL1066405 | 0.98 | — | — | |
| SCHEMBL1927815 | 0.93 | — | — | |
| SCHEMBL1114446 | 0.93 | — | — | |
| SCHEMBL56745 | 0.93 | — | — | |
| Hydrochloric Acid SCHEMBL1114699 | 0.91 | CCR2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481541-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-07-09 | — | — | US | claimed |
| EP-2550274-A1 | PYRROLOPYRAZINE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2013-01-30 | — | — | EP | claimed |
| US-20100029941-A1 | PREPARATION OF (R)-3-AMINOPIPERIDINE DIHYDROCHLORIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-04 | — | — | US | claimed |
| US-20250326739-A1 | CD38 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4532483-A1 | CD38 MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| WO-2023235880-A1 | CD38 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| CN-110511213-B | Immunomodulator | 成都先导药物开发股份有限公司 | 2021-10-19 | — | — | CN | disclosed |
| WO-2021064077-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS IRAK4 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-08 | — | — | WO | disclosed |
| JP-2000086481-A | SKIN PREPARATION FOR EXTERNAL USE | SHISEIDO CO LTD | 2000-03-28 | — | — | JP | disclosed |
| EP-0871628-A1 | QUINOLIZINONE TYPE COMPOUNDS | Abbott Laboratories (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5726182-A | TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1998-03-10 | — | — | US | disclosed |
| US-5599816-A | BACTERICIDE | ABBOTT LABORATORIES (US) | 1997-02-04 | — | — | US | disclosed |
| WO-1996039407-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-12 | — | — | WO | disclosed |
| CN-1137273-A | Quinolizinone type compounds | ABBOTT LAB (US) | 1996-12-04 | — | — | CN | disclosed |
| US-5580872-A | ADMINISTERING IN THE TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1996-12-03 | — | — | US | disclosed |
| EP-0723545-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-07-31 | — | — | EP | disclosed |
| WO-1995010519-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1995-04-20 | — | — | WO | disclosed |